Condition
Stage IVA Nasopharyngeal Carcinoma
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Withdrawn1
Active Not Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02135042Phase 2Active Not Recruiting
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT04231864Phase 2Withdrawn
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
NCT03049358Not ApplicableTerminated
Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer
Showing all 3 trials